| Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors W Wang, Q Li, T Yamada, K Matsumoto, I Matsumoto, M Oda, ... Clinical Cancer Research 15 (21), 6630-6638, 2009 | 363 | 2009 |
| AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells H Taniguchi, T Yamada, R Wang, K Tanimura, Y Adachi, A Nishiyama, ... Nature communications 10 (1), 259, 2019 | 280 | 2019 |
| Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort S Yano, T Yamada, S Takeuchi, K Tachibana, Y Minami, Y Yatabe, ... Journal of thoracic oncology 6 (12), 2011 | 257 | 2011 |
| EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition T Nakagawa, S Takeuchi, T Yamada, H Ebi, T Sano, S Nanjo, D Ishikawa, ... Cancer research 73 (8), 2428-2434, 2013 | 193 | 2013 |
| Immune checkpoint inhibitors for lung cancer treatment: a review K Onoi, Y Chihara, J Uchino, T Shimamoto, Y Morimoto, M Iwasaku, ... Journal of clinical medicine 9 (5), 1362, 2020 | 145 | 2020 |
| Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer IS Donev, W Wang, T Yamada, Q Li, S Takeuchi, K Matsumoto, T Yamori, ... Clinical Cancer Research 17 (8), 2260-2269, 2011 | 129 | 2011 |
| Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer T Yamada, K Matsumoto, W Wang, Q Li, Y Nishioka, Y Sekido, S Sone, ... Clinical Cancer Research 16 (1), 174-183, 2010 | 127 | 2010 |
| Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells T Yamada, S Takeuchi, J Nakade, K Kita, T Nakagawa, S Nanjo, ... Clinical cancer research 18 (13), 3592-3602, 2012 | 125 | 2012 |
| Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant … W Wang, Q Li, S Takeuchi, T Yamada, H Koizumi, T Nakamura, ... Clinical Cancer Research 18 (6), 1663-1671, 2012 | 119 | 2012 |
| Tumor neovascularization and developments in therapeutics Y Katayama, J Uchino, Y Chihara, N Tamiya, Y Kaneko, T Yamada, ... Cancers 11 (3), 316, 2019 | 118 | 2019 |
| Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer T Yamada, S Hirai, Y Katayama, A Yoshimura, S Shiotsu, S Watanabe, ... Cancer medicine 8 (4), 1521-1529, 2019 | 111 | 2019 |
| Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status K Fukuda, S Takeuchi, S Arai, R Katayama, S Nanjo, A Tanimoto, ... Cancer research 79 (7), 1658-1670, 2019 | 98 | 2019 |
| Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer N Nishioka, J Uchino, S Hirai, Y Katayama, A Yoshimura, N Okura, ... Journal of clinical medicine 8 (4), 450, 2019 | 95 | 2019 |
| Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer T Nakagawa, S Takeuchi, T Yamada, S Nanjo, D Ishikawa, T Sano, K Kita, ... Molecular cancer therapeutics 11 (10), 2149-2157, 2012 | 94 | 2012 |
| ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer N Okura, N Nishioka, T Yamada, H Taniguchi, K Tanimura, Y Katayama, ... Clinical Cancer Research 26 (9), 2244-2256, 2020 | 93 | 2020 |
| Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury K Nagata, Y Iwasaki, T Yamada, T Yuba, K Kono, S Hosogi, S Ohsugi, ... Respiratory medicine 101 (4), 800-807, 2007 | 91 | 2007 |
| Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer A Tanimoto, S Takeuchi, S Arai, K Fukuda, T Yamada, X Roca, ST Ong, ... Clinical Cancer Research 23 (12), 3139-3149, 2017 | 90 | 2017 |
| Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer R Wang, T Yamada, K Kita, H Taniguchi, S Arai, K Fukuda, M Terashima, ... Nature communications 11 (1), 4607, 2020 | 85 | 2020 |
| Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer S Takeuchi, W Wang, Q Li, T Yamada, K Kita, IS Donev, T Nakamura, ... The American journal of pathology 181 (3), 1034-1043, 2012 | 81 | 2012 |
| Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC RR Arasada, K Shilo, T Yamada, J Zhang, S Yano, R Ghanem, W Wang, ... Nature communications 9 (1), 3198, 2018 | 73 | 2018 |
